Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

carcinogen.

Contraindications

PEGINTRON is contraindicated in patients with hypersensitivity to PEGINTRON or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. INTRON A (Interferon alfa-2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON A or any component of the product, autoimmune hepatitis, and decompensated liver disease. PEGINTRON or INTRON A in combination with REBETOL therapy is additionally contraindicated in patients with hypersensitivity to ribavirin or any other component of the product, women who are pregnant, men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL/min.

Avoid Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGI
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014 Though therapies ... technologies are expected to show an annual increase of ... value of nearly $1 billion, according to Kalorama Information,s ... from proprietary stem cell therapeutics that have gained or ... "As drug developers tackle ever more complicated ...
(Date:10/30/2014)... Stryker Orthopaedics, the Official Joint Replacement Products ... out its debut year of the relationship at the ... This marks the eleventh tournament stop along ... brand has activated on-site with the "Stryker Mobility Zone" ... the importance of joint health.  The ...
(Date:10/30/2014)... -- Boston Scientific Corporation (NYSE: BSX ) ... Annual Healthcare Conference on Tuesday, November 11, 2014 in ... , executive vice president and chief financial officer, will ... 8:00 a.m. PT followed by a question and answer ... and question and answer session will be available to ...
Breaking Medicine Technology:Report: Stem Cell Technologies Market Growing 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2
... WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 ... outside the United States and Canada, and Intercell AG ... analysis from the Phase II/III clinical trial evaluating V710, ... (S. aureus) infection, the independent Data Monitoring Committee (DMC) ...
... (EURONEXT: SAN and NYSE: SNY ) announced ... Corporation, which is now a wholly-owned subsidiary of sanofi-aventis. ... conclusion of a subsequent offering period relating to sanofi-aventis, ... of common stock for US$74.00 in cash and one ...
Cached Medicine Technology:Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 2Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 3Sanofi-Aventis Completes Acquisition of Genzyme Corporation 2Sanofi-Aventis Completes Acquisition of Genzyme Corporation 3Sanofi-Aventis Completes Acquisition of Genzyme Corporation 4
(Date:10/31/2014)... (PRWEB) October 31, 2014 Activz ... Activz Silver line offering natural silver healing ... For over a century, silver has been used to ... Activz Silver products is the most advanced version available. ... a unique chemical structure that supports the existing healing ...
(Date:10/31/2014)... for low back pain caused by spinal stenosis varies ... a new report says. "Nearly 80 percent of ... in their lives, and about 30 million people a ... co-author Brook Martin, of the Dartmouth Institute of Health ... release. In spinal stenosis, thickening of tissue surrounding ...
(Date:10/31/2014)... News) -- Obesity increases the risk of certain types ... two new U.S. studies show. One study of ... obese increased the risk for estrogen receptor-negative and progesterone ... this for a long time for white women, but ... study author Esther John, a senior research scientist at ...
(Date:10/31/2014)... – New research suggests that insomnia is a major ... other unintentional fatal injuries. The results underscore the importance ... National Healthy Sleep Awareness Project. , Results show that ... dose-dependent manner with the number of insomnia symptoms present. ... times more likely to die from a fatal injury ...
(Date:10/31/2014)... have invented a lab device to give cancer researchers ... that tumor cells spread through the body, causing more ... on precisely how tumor cells travel, the device could ... The inventors, from the university,s Whiting School of Engineering ... images from their new system recently in the journal ...
Breaking Medicine News(10 mins):Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
... Lisa Maas, executive director of Californians Allied ... response to an Associated Press/Stanford University poll released today ... for personal injury lawyers to sue health care providers. ... hospitals, community clinics, local governments, dentists and other groups ...
... , , FAIRFIELD, N.J., Nov. 19 Monogram ... it had completed the acquisition of Triad Therapeutics, Inc. ... Under the terms of the Stock Purchase and ... outstanding shares of Triad in exchange for approximately 95% ...
... ... flies have uncovered a new function for a gene whose human equivalent may play a critical ... (Vocus) November 19, ... function for a gene whose human equivalent may play a critical role in schizophrenia., , ,Scientists ...
... , - Q3 Gross Profit Increases 77%; ... 2008 , - Q3 2009 Operating Income Increases 121% from same ... from same period in 2008 , MORTON GROVE, Ill., Nov. 16 ... nutritious, probiotic dairy beverage called kefir, announced today for the third ...
... time for consolidating memories, researchers find , THURSDAY, Nov. ... and enhance associated memories upon waking, new research finds. ... called spatial memory, researchers at Northwestern University in Chicago ... and played corresponding sounds, like a cat meowing and ...
... COLUMBIA, Mo. Effective communication of health news is ... populations who experience health disparities, or inequalities in health ... Human Services. As media researchers search for better methods ... published in Public Relations Review has found ...
Cached Medicine News:Health News:National Poll Confirms Americans Support Curbs on Malpractice Lawsuits 2Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2Health News:Schizophrenia Gene's Role May Be Broader, More Potent, than Thought 2Health News:Schizophrenia Gene's Role May Be Broader, More Potent, than Thought 3Health News:Schizophrenia Gene's Role May Be Broader, More Potent, than Thought 4Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 2Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 3Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 4Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 5Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 6Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 7Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 8Health News:Sounds May Help Solidify Memories While Asleep 2Health News:Highlighting racial disparities increases coverage and effectiveness of health news 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: